Helio Genomics Launches Game-Changing Cancer Detection Test in Partnership with Quest Diagnostics

Helio Genomics has officially entered the market with its innovative cancer detection test, HelioLiver, marking a significant milestone in early liver cancer diagnosis. This launch is made possible through a strategic partnership with Quest Diagnostics, one of the United States’ leading diagnostic testing providers. Dr. Bharat Tewarie, the newly appointed CEO, aims to leverage established partnerships to expedite market entry and enhance accessibility for healthcare professionals and patients alike.

A Strategic Partnership Driving Growth

The partnership with Quest Diagnostics is pivotal for Helio Genomics, as it connects the company’s cutting-edge testing capabilities to a network of over 7,700 patient service centers and in-office phlebotomists. Dr. Tewarie emphasizes that collaborations with established entities like Quest play a crucial role in scaling operations efficiently. As they transition into commercial availability across the nation, the HelioLiver test is being marketed as a laboratory-developed test while the company awaits FDA approval. With a premarket approval application submitted in 2024, expectations for regulatory clearance are set for the second quarter of 2025.

Seamless Integration with Healthcare Systems

Under the Quest collaboration, healthcare providers can easily access the HelioLiver test through their existing Quest accounts and electronic health records. This seamless integration is not only beneficial for healthcare practitioners but also enhances patient experience. In addition to this recent partnership, Helio Genomics previously announced a collaboration with LiverRight Inc., a specialized virtual clinic focusing on liver diseases. This comprehensive network aims to utilize Helio’s advanced testing, including the recently launched LiverTrace, enhancing early detection of liver cancer and improving clinical outcomes.

The Innovation Behind HelioLiver and LiverTrace

HelioLiver and LiverTrace represent breakthroughs in the early detection of liver cancer. The LiverTrace test utilizes advanced AI algorithms and machine learning to identify cancer biomarkers before tumors become detectable through traditional ultrasound imaging. This pioneering approach helps in diagnosing liver cancer at earlier stages, potentially improving treatment success rates. Through partnerships with organizations like the American Liver Foundation, Helio Genomics is raising awareness and pushing the envelope in liver cancer diagnostics.

An Expanding Portfolio of Diagnostics

Looking ahead, Helio Genomics is not stopping with the launch of HelioLiver. Dr. Tewarie has indicated that the company is exploring the development of additional tests related to liver cancer. As part of its expanding diagnostic portfolio, Helio Genomics aims to introduce two new assessments: one that tracks patient responses to liver cancer treatments and another designed to monitor recurrence post-treatment or liver transplantation. This focus on comprehensive diagnostic solutions highlights Helio’s commitment to early cancer detection, making it a key player in the healthcare market.

Commitment to Early Cancer Diagnostics

Helio Genomics is firmly rooted in the mission of early cancer diagnostics. The company is dedicated to making diagnoses accessible and timely, which can significantly affect patient outcomes. By developing a range of tests that cater to different aspects of liver cancer management, Helio demonstrates a proactive approach to healthcare. Dr. Tewarie’s vision to expand the company’s product line showcases a commitment to innovation while ensuring patients receive the best available care.

Future Outlook

As Helio Genomics continues to expand its testing offerings and strengthen its partnerships, the future looks promising for both the company and the patients it serves. The integration of the HelioLiver test through Quest Diagnostics represents a shift toward more accessible and efficient diagnostic practices in the fight against liver cancer. With regulatory approval on the horizon and an expanding test portfolio, Helio Genomics is poised to become a leader in early cancer detection, ultimately saving lives through timely diagnosis and intervention.

In conclusion, the collaboration with Quest Diagnostics not only accelerates Helio Genomics’ product launch but also highlights the importance of strategic partnerships in advancing healthcare technology. As the company forges ahead, it stands committed to revolutionizing cancer diagnostics and making significant strides in the fight against liver cancer.